Addition of a drug known as a cyclin inhibitor increased survival rates to 70 percent among patients with the most common form of breast cancer, researchers sayCHICAGO - A new form of drug drastically improves survival rates of young women with the most common form of breast cancer, researchers said on Saturday, citing the results of an international clinical trial. The findings, presented at the annual meeting of the American Society of Clinical Oncology in Chicago, showed that the addition of a drug known as a cyclin inhibitor increased survival rates to 70 percent. Lead author Sara Hurvitz told AFP the study focused on hormone receptor-positive breast cancer, which accounts for two-thirds of all breast cancer cases among younger women and have in the past generally been treated by therapies that block estrogen production. The treatment is less toxic than traditional chemotherapy because it more selectively targets cancerous cells, blocking their ability to multiply. "These are patients who tend to be diagnosed later, at a later stage in their disease, because we don't have great screening modalities for young women," said Hurvitz.

Source: Bangkok Post June 01, 2019 17:48 UTC